On March 30, 2026, Aurinia Pharmaceuticals Inc. reported entering into a merger agreement with Kezar Life Sciences, involving a cash offer of $6.955 per share plus contingent value rights for all of Kezar's outstanding shares. The merger is expected to close in the second quarter of 2026, pending certain conditions.